Moore Capital Management, LP Intellia Therapeutics, Inc. Transaction History

Moore Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $11.3 Million - $15.5 Million	-111,726 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $6.73 Million - $8.99 Million	50,833 Added 83.48%	111,726 $15 Million
Q2 2021 Aug 16, 2021	SELL	$60.88 - $161.91 $7.58 Million - $20.2 Million	-124,541 Reduced 67.16%	60,893 $9.86 Million
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $6.43 Million - $11.5 Million	138,012 Added 291.03%	185,434 $14.9 Million
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $892,956 - $3.01 Million	47,422 New	47,422 $2.58 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.